Amantadine

Generic Name: Amantadine

Brand Names: Gocovri, Osmolex

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N

CAS Number: 768-94-5

Unique Ingredient Identifier: BF4C9Z1J53

Background: An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps ...

Indication: For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Associated Conditions: Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism

Associated Therapies: -

Clinical Trials

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorders

Interventions: Drug: olanzapine
Behavioral: Wellness education
Drug: amantadine
Drug: metformin
Drug: zonisamide

First Posted Date: 2006-11-22

Last Posted Date: 2009-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 199

Registration Number: NCT00401973

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients

Phase 3

Completed

Conditions: HCV Infection
Hepatitis C, Chronic

First Posted Date: 2005-09-22

Last Posted Date: 2007-06-13

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 131

Registration Number: NCT00221624

Locations: 🇫🇷
Service d'hépato-Gastro-Entérologie - Hôpital Haut Leveque - avenue de Magellan, Pessac, France

Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy

Phase 1

Conditions: Hyperalgesia
Prostate Cancer
Pain

First Posted Date: 2005-09-16

Last Posted Date: 2006-03-14

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 132

Registration Number: NCT00188383

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

Phase 2

Completed

Conditions: Cocaine-Related Disorders

Interventions: Drug: Propranolol
Drug: Placebo
Drug: Amantadine

First Posted Date: 2005-09-12

Last Posted Date: 2017-01-12

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 199

Registration Number: NCT00158132

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients

Phase 3

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2005-09-05

Last Posted Date: 2005-09-05

Lead Sponsor: UMC Utrecht

Target Recruit Count: 390

Registration Number: NCT00146016

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands

Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)

Phase 4

Withdrawn

Conditions: Dementia

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2005-08-05

Last Posted Date: 2017-08-14

Lead Sponsor: Johns Hopkins University

Registration Number: NCT00127114

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Outpatient General Clinical Research Center, Baltimore, Maryland, United States

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Phase 3

Terminated

Conditions: Hepatitis C, Chronic

First Posted Date: 2005-07-22

Last Posted Date: 2005-07-29

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 405

Registration Number: NCT00122629

Locations: 🇫🇷
Service d'Hépato-Gastroentérologie Hopital Hotel Dieu, Lyon Cedex, France

Treatment of Huntington's Chorea With Amantadine

Phase 2

Completed

Conditions: Chorea
Huntington's Disease

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 25

Registration Number: NCT00001930

Locations: 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States

Prepulse Inhibition of Startle in Cocaine Dependence - 7

Phase 1

Completed

Conditions: Cocaine-Related Disorders
Substance-Related Disorders

First Posted Date: 2001-04-18

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT00015249

Locations: 🇺🇸
New York MDRU, New York, New York, United States

Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4

Phase 2

Completed

Conditions: Cocaine-Related Disorders

First Posted Date: 1999-09-21

Last Posted Date: 2016-07-11

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT00000301

Locations: 🇺🇸
Friends Research Institute, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy